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INTRODUCTION
HIV infection is a chronic inflammatory disease in 
which several immunological and functional disorders, 
associated to a pro-inflammatory change in the gut 
microflora, are described1. 
Recent advances in medical research have reported 
the importance of intestinal microbiota in influenc-
ing “the gut-brain axis” (GBA), linking cognitive and 
emotional centers of the brain with peripheral enteric 
nervous system and intestinal functions2. Neural and 
endocrine networks, immune and humoral links ap-
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Other relevant conditions in his medical history were 
osteopenia/osteoporosis and a partial impairment of neu-
rocognitive performance without severe reductions in 
working capacity, evidenced from 2015 (Table 3). 
On June 2016, the patient spontaneously started a 
healthy lifestyle based on a change in eating habits and 
on the abandonment of physical inactivity. A Mediterra-
nean diet with restricted caloric intake was adopted and 
a probiotic supplementation with daily dose of 2 sachets 
was started. The multistrain probiotic used contained 
Bifidobacteria (B. breve DSM 24732, B. longum DSM 
24736, B. infantis DSM 24737), Lactobacilli (L. acidoph-
ilus DSM 24735, L. plantarum DSM 24730, L. paraca-
sei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 
24734) and Streptococcus thermophilus DSM 24731. 
At the same time, he began a regular physical ac-
tivity, and gradually came to make jogging twice a 
week for about 40 minutes each time, and swimming 
for 60 minutes one time, weekly. 
Six months after the start of this healthy lifestyle, the 
patient underwent to a clinical, neuropsychological and 
viro-immunological follow-up. As reported in table 2, a 
reduction peripheral in immune-activation was observed. 
Moreover, HIV-RNA remained undetectable and the 
number of CD4+ increased from 411 to 532 cells/mmc. 
Also the metabolic parameters were improved with bet-
ter control of the dyslipidemia previous reported.
The evaluation of neuropsychological assessment was 
performed through a complete neuropsychological test 
battery (Mini-Mental State Examination followed by 
specific tests exploring the main cognitive domains such 
as memory, attention, executive function, language). A 
parallel form of RAVLT (immediate and delayed recall) 
was used, according to the Italian validation. At the 
same time, to assess psychological manifestations (alex-
ithymia, depression, state and trait anxiety) the patient 
was evaluated through a set of questionnaires including 
State-Trait Anxiety Inventory Y-1 and Y-2, Toronto Alex-
ithymia Scale-20 and Beck Depression Scale II18-31. When 
pear to affect this bidirectional interaction between 
microbiota and GBA2. In particular, the gut microbiota 
is involved in the regulation of cognition, mood and 
anxiety and can impact cognitive and mood functions 
in different ways, i.e. by releasing bacterial metabolites 
or producing neuroactive substances3-5. 
Probiotic supplementation has shown positive ef-
fects on the control of the dysbiosis associated to many 
chronic inflammatory bowel conditions and diseases6. 
Moreover, recent studies conducted in HIV popula-
tion have reported that probiotic supplementation was 
associated to I) a recovery of the integrity of the gut 
epithelial barrier; II) a reduction of intraepithelial lym-
phocytes and enterocyte apoptosis; III) a reduction in 
the levels of immune activation on CD4 T-lymphocytes, 
for both markers CD38 and HLA-DR, high sensitivity 
C-Reactive Protein (hs-CRP) and lipopolysaccharide 
binding protein (LBP) plasma levels; IV) a significant 
reduction of neopterin in cerebrospinal fluid (CSF) and 
indolamine-2,3-dioxygenase (IDO) mRNA levels in 
gut-associated lymphoid tissue (GALT); V) an improve-
ment in same neurocognitive functions7-10. Despite these 
preliminary observations, more evidence is needed to 
better understand the contribution of the probiotics in 
modulating Gut-Brain Axis in HIV patients. In the 
same way, interesting studies have showed that also a 
regular physical activity may result in I) a decrease in 
chronic inflammation and related immune activation; 
II) a concomitant reduction in the damages related to 
non-AIDS defining illnesses; III) an improvement in 
overall neuropsychological function11. Considering the 
importance of this preliminary evidence, several trials 
are ongoing to accurately assess these data12-18.
CASE REPORT
Hereby we present the case of a 56-year-old Cauca-
sian man, who has sex with men (MSM), diagnosed 
for HIV infection in 1989. The Patient signed both 
written informed consent and consent for publication 
of anonymized data. He was lost to follow up since 
1994, when he was admitted to our Hospital because 
of with Pneumocisis jirovecii pneumonia and atypical 
mycobacterial infection, with a nadir of CD4+ count of 
1/mmc (CDC AIDS Score: C3). He underwent various 
antiretroviral regimens with repeated treatment fail-
ures due initially to the poor adherence, and after to 
the side effects of therapy (i.e. peripheral neuropathy, 
lipodystrophy and dyslipidemia). For these reasons, he 
changed several antiretroviral treatments as reported 
in Table 1. The current combined antiretroviral therapy 
(cART), started in May 2015, is Dolutegravir, Daruna-
vir/r, Saquinavir and Emtricitabine.
The immune-virologic control was obtained in 2011 
with persistent undetectable HIV viral load and stable 
recover of lymphocytes T-CD4+ >350 cell/mmc. The 
levels of immune activation on CD4+ and CD8+ T-lym-
phocytes, for both markers CD38 and HLA-DR and 
their simultaneous expression, recorded at April 2016, 
were showed in Table 2.
Table 1. History of antiretroviral treatments.
1995-1997 ZIDOVUDINE + DIDANOSINE
1997-1997 SAQUINAVIR + LAMIVUDINE + 
 STAVUDINE
1999-2003 EFAVIRENZ + LAMIVUDINE + 
 ZIDOVUDINE
2003-2004 ATAZANAVIR/r + SAQUINAVIR + 
 TENOFOVIR
2004-2007 TIPRANAVIR/r + ABACAVIR + 
 TENOFOVIR
2007-2008 TENOFOVIR + EMTRICITABINE + 
 DARUNAVIR/r
2008-2012 LOPINAVIR/r + TENOFOVIR+ 
 ENFUVIRTIDE + LAMIVUDINE + 
 ZIDOVUDINE + RALTEGRAVIR
2012-2013 TENOFOVIR + EMTRICITABINE + 
 RALTEGRAVIR + EFAVIRENZ
2013-2014 DARUNAVIR/r + ETRAVIRINE
2014-2015 DARUNAVIR/r + SAQUINAVIR + 
 EMTRICITABINE
2015-today DOLUTEGRAVIR + DARUNAVIR/r + 
 SAQUINAVIR + EMTRICITABINE
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the GBA in neurocognitive disorders. These data indicate 
that alterations in microbiota quality and amount can 
substantially affect the brain physiology, and differential 
microbial composition is associated with alterations in 
behavior and cognition33-35. Studies exploring the effects 
of probiotics on gut microbiota composition have shown 
that supplementation can play a protective role on mod-
ification of mood and behavior, worsening of cognition 
related to alterations of microbioma and to dysbiosis36-38. 
In our report, the patient regularly took a high concen-
tration multi-strain probiotic powder supplement twice 
a day for six months as documented by the increase of 
fecal Bifidobacteria spp, compared to their basal level. 
After six months of probiotic intake, our patient 
presented a significant improvement of his performance 
in the most of neuropsychological and behavioral tests. 
The possible effect of probiotic supplementation on 
neurocognitive performances could be linked to differ-
ent pathophysiologic mechanisms: in fact, experimental 
and clinical evidence suggest that gut microbiota inter-
neurocognitive data were analyzed, a significant differ-
ence between T0 and T6 was observed: in fact, most of 
test scores increased significantly as showed in table 3. 
By contrast, no significant differences were observed 
for FAB (Frontal Assessment Battery), TMTA (Trail 
Making Test A), Verbal Span-Digit Forward, Verbal 
Span-Digit Back, BDI II (Beck Depression Scale), AAT 
(Aachen Aphasia Test), CBTT- Forward (Corsi block tap-
ping task), CBTT-Backward (Corsi block tapping task) 
examined before and after probiotic intake.
The increase of fecal Bifidobacteria spp, compared 
to their basal level, confirmed the adherence to the 
probiotic supplementation. 
DISCUSSION
Neurocognitive disorders are commonly reported in 
cART treated HIV patients32. Recently, pivotal studies 
have increased the understanding of the role played by 
Table 2. Changes in immune-activation levels before and after 6 months of probiotic supplementation.
 CD4+  CD4+ CD38+  CD4+ HLA-DR+  CD4+ CD38+ HLA-DR+
 % % % % 
   
T0 17.70 13.76 6.52 2.31
T6 31.25 2.48 3.47 0.32
 CD8+  CD8+ CD38+ CD8+ HLA-DR+  CD8+ CD38+ HLA-DR+ 
 % %   %  % 
   
T0 70.38 6.20 9.60 4.38
T6 64.65 0.49 3.28 0.79
Table 3. Results of neuropsychological test administered before and after 6 months of probiotic supplementation. 
  Results at T0  Results at T6
MMSE (Mini Mental State Examination) 25 30
RAVLT (Rey Auditory Verbal Learning Test Immediate Recall) 29 53
RAVLT (Rey Auditory Verbal Learning Test Delayed Recall) 6 15
RAVLT (Rey Auditory Verbal Learning Recognition) 90 98
ROCF (Rey-Osterrieth Complex Figure Copy Immediate recall) 10 20
ROCF (Rey-Osterrieth Complex Figure Copy Delayed Recall) 12 24
FAB (Frontal Assessment Battery) 12 14
PVF (Phonological Verbal Fluency) 18 45
SVF (Semantic Verbal Fluency) 32 47
TMTA (Trail Making Test A) 50 49
TMTB (Trail Making Test B) 110 130
Verbal Span-Digit Forward 3.5 6
Verbal Span-Digit Back 4 5
Tas-20 (Toronto Alexithymia Scale-20) 40 55
BDI II (Beck Depression Scale) 12 15
AAT (Aachen Aphasia Test) 9 9
CBTT- Forward (Corsi block tapping task) 9 9
CBTT-Backward (Corsi block tapping task) 3 4
STEP Time (Time and Weight Estimation test) 14 21
STEP Weight (Time and Weight Estimation test) 13 24
STEP Total (Time and Weight Estimation test) 29 47
STAY Y-1 (State-Trait Anxiety Inventory) 45 60
STAY Y-2 (State-Trait Anxiety Inventory) 60 100
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grate these non-pharmacological tools into an overall 
approach based on a focus on the patient’s lifestyle. 
Therefore, our findings seem to be encouraging, but 
large studies and clinical trials, carried out with specific 
methodological procedures, are needed to support the 
validity of current preliminary assumptions.
ConfliCt of interests:  
The Authors declare that they have no conflict of inte-
rests.
REFERENCES
 1. Ziberman-Schapira G, Zmora N, Itav S, Bashiardes S, 
Elinav H, Elinav E. The gut microbiome in human immu-
nodeficiency virus infection. BMC Medicine 2016; 14: 83.
 2. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-
brain axis: interactions between enteric microbiota, central 
and enteric nervous systems. Ann Gastroenterol 2015; 28: 
203-209.
 3. Cryan JF, Dinan TG. Mind-altering microorganisms: the 
impact of the gut microbiota on brain and behaviour. Nat 
Rev Neurosci 2012; 13: 701-712. 
 4. Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan 
TG. The probiotic Bifidobacteria infantis: an assessment of 
potential antidepressant properties in the rat. J Psychiatr Res 
2008; 43: 164-174.
 5. Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, Dinan 
TG. Effects of the probiotic Bifidobacterium infantis in the 
maternal separation model of depression. Neurosci 2010; 
170: 1179-1188.
 6. Rohatgi S, Ahuja V, Makharia GK, Rai T, Das P, Dattagupta 
S. VSL#3 induces and maintains short-term clinical re-
sponse in patients with active microscopic colitis: a two-
phase randomised clinical trial. BMJ Open Gastroenterol 
2015; 2: e000018.
 7. d’Ettorre G, Rossi G, Scagnolari C, Andreotti M, Giustini 
N, Serafino S, Schietroma I, Scheri GC, Fard SN, Trinchieri 
V, Mastromarino P, Selvaggi C, Scarpona S, Fanello G, 
Fiocca F, Ceccarelli G, Antonelli G, Brenchley JM, Vullo 
V. Probiotic supplementation promotes a reduction in T-cell 
activation, an increase in Th17 frequencies, and a recovery 
of intestinal epithelium integrity and mitochondrial mor-
phology in ART-treated HIV-1-positive patients. Immun 
Inflamm Dis 2017; 5: 244-260.
 8. Scagnolari C, Corano Scheri G, Selvaggi C, Schietroma I, 
Najafi Fard S, Mastrangelo A, Giustini N, Serafino S, Pinac-
chio C, Pavone P, Fanello G, Ceccarelli G, Vullo V, d’Ettorre 
G. Probiotics differently affect gut-associated lymphoid tis-
sue indolamine-2,3-dioxygenase mRNA and cerebrospinal 
fluid neopterin levels in antiretroviral-treated hiv-1 infected 
patients: a pilot study. Int J Mol Sci 2016; 17. pii: E1639.
 9. d’Ettorre G, Ceccarelli G, Giustini N, Serafino S, Calantone 
N, De Girolamo G, Bianchi L, Bellelli V, Ascoli-Bartoli T, 
Marcellini S, Turriziani O, Brenchley JM, Vullo V. Pro-
biotics reduce inflammation in antiretroviral treated, hiv-
infected individuals: results of the “probio-HIV” clinical 
trial. PLoS One 2015; 10: e0137200.
10. Ceccarelli G, Fratino M, Selvaggi C, Giustini N, Serafino 
S, Schietroma I, Corano Scheri G, Pavone P, Passavanti G, 
Alunni Fegatelli D, Mezzaroma I, Antonelli G, Vullo V, 
Scagnolari C, d’Ettorre G. A pilot study on the effects of 
probiotic supplementation on neuropsychological perfor-
mance and microRNA-29a-c levels in antiretroviral-treated 
HIV-1-infected patients. Brain Behav 2017; 7: e00756.
act not only locally with gastro-intestinal cells, but also 
directly with central nervous system (CNS) through 
metabolic and neuroendocrine pathways2.
A recent study shows that IDO activity (and trypto-
phan metabolism), involved in the neuro-inflammation 
and participating in the onset of neurocognitive disor-
ders, was significantly reduced by probiotic supplemen-
tation. In fact, IDO mRNA expression in the GALT 
and CSF neopterin levels decreased at the same time 
in cART treated HIV patients8. Moreover, according to 
results obtained in animal models, the manipulation of 
microbial taxa through probiotic supplementation may 
modulate the hippocampal regions controlling mem-
ory functions and attenuating age-related alterations 
in the hippocampus by increasing the brain-derived 
neurotrophic factor (BDNF) expression39,40. Based on 
these preliminary evidence probiotics supplementation 
seems to be an effective and safe approach to improve 
neurocognitive performance, and in particular memory 
functions, in HIV-1 positive patients. 
As previous reported, the reduction in the levels of 
peripheral and CNS immune activation of was observed 
in cART treated patient after supplementation with 
specific multistrain probiotic formulation8,9. Given that 
neuroinflammation is considered a major contributor to 
the behavior and cognitive changes observed in HIV 
infection, probiotics could be a potentially useful tool 
to reduce the negative effects of immune activation also 
in the CNS, in association with cART therapy. 
The improvement of cardio-metabolic assessment is 
usually well-known effect in subjects that have under-
gone regular physical activity: the increase of maximum 
rate of oxygen consumption (trough Rockport walk test) 
and an amelioration of lipid and glucose metabolism 
parameters are commonly reported. Less known are 
the potential benefits of regular physical exercise on 
immune-activation and neurocognitive performance. A 
comprehensive review of data available suggests that 
regular physical activity is a beneficial non-pharma-
cological intervention to reduce chronic inflammation, 
to improve the treatment of HIV residual disease and 
non-AIDS-defining illnesses in cART-treated HIV-in-
fected individuals11. It remains to define the type and 
intensity of physical activity that is appropriate to 
diminish effectively the immune-activation, consider-
ing that it is well known that certain types of physical 
exercises may be pro-inflammatory stimuli11. 
CONCLUSIONS
Despite the limitations justified by the complexity of 
the matter, the available findings of studies indicate that 
neurocognitive functions are significantly improved af-
ter a long-term probiotic supplementation, supporting 
the hypothesis that modifications of the microbioma 
can provide specific neurological benefits in HIV-1 pa-
tients and reduce peripheral immune-activation. Also, 
physical activity seems to contribute to achieve the 
same goals, though other pathophysiological pathways. 
Our observations suggest that it is important to inte-
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